protein tyrosine phosphatase receptor type MGenealiases: PTPRL1 · R-PTP-MU · RPTPM · RPTPU · hR-PTPu
Q-omics provides the consensus-scored PTPRM profile across patient tissues and cancer cell-line models. PTPRM expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PTPRM is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, PTPRM protein abundance shows 23,920 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where PTPRM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPRM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPRM survival associations across molecular data types. PTPRM RNA expression shows survival associations in the most cancer types (26), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPRM RNA expression–survival associations across cancer types. High PTPRM expression shows unfavorable associations in CESC, LUSC, MESO and STAD, but favorable associations in KIRC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PTPRM RNA expression.
This table summarizes PTPRM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PTPRM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPRM shows lower tumor expression in KICH, LUSC, LUAD, UCEC and BRCA and higher tumor expression in KIRC. The KICH box plot shows higher PTPRM RNA expression in normal versus tumor tissue (log2 FC = −2.154, t-test p < 0.001).
This table shows molecular features associated with PTPRM in patient tissues and cancer cell lines. In patient samples, PTPRM shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPRM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
